Hospital
Hardin Memorial Hospital
Hardin Memorial Hospital was paid $37.24M by Medicaid between Jan 2018 and Jan 2021, across 418 billing codes. Its largest line is 99284, emergency room visit (serious) — 12% of everything it billed.
33Billing provider infoHARDIN MEMORIAL HOSPITAL
ELIZABETHTOWN, KY 42701
ELIZABETHTOWN, KY 42701
33aNPI1619931466assigned 04/17/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$37.24M
24GClaims1,293,632
24DCodes billed418
24AFirst – last monthJan 2018 – Jan 2021
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#17 of 36
Median peer was paid$36.08M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 409,811 | $12.36M | |
| 2019 | 450,748 | $12.82M | |
| 2020 | 414,240 | $11.58M | |
| 2021 | 18,833 | $480K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 17,457 | 15,443 | $4.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.8% | 26,704 | 23,677 | $3.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.3% | 11,646 | 9,831 | $2.73M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.1% | 14,293 | 12,953 | $1.92M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.1% | 6,740 | 5,929 | $1.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.1% | 18,528 | 14,178 | $784K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2.0% | 2,635 | 2,136 | $740K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.8% | 13,346 | 8,261 | $667K |
| G0378 | Hospital observation service, per hour | 1.7% | 1,903 | 1,614 | $625K |
| 80053 | Comprehensive metabolic panel | 1.5% | 81,327 | 55,671 | $554K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 1.4% | 1,525 | 1,356 | $536K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 1.4% | 1,009 | 855 | $533K |
406 more codes
| 47562 | 1.4% | 197 | $526K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 1.4% | 1,535 | $516K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.3% | 1,186 | $478K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1.3% | 1,231 | $466K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.2% | 4,971 | $435K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 2,470 | $410K |
| 41899 | Unlisted procedure, dentoalveolar structures | 1.0% | 626 | $381K |
| J3490 | Unclassified drugs | 1.0% | 67,584 | $376K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,426 | $371K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 18,954 | $369K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 531 | $364K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 929 | $342K |
| 36415 | Collection of venous blood by venipuncture | <1% | 147,681 | $338K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,766 | $320K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 67,165 | $313K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 342 | $301K |
| 72141 | <1% | 875 | $293K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,898 | $285K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 5,204 | $281K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,192 | $260K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 288 | $259K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,222 | $255K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,448 | $254K |
| 71250 | <1% | 1,665 | $252K | |
| 59025 | Fetal non-stress test | <1% | 3,676 | $249K |
| 73221 | <1% | 733 | $245K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 5,774 | $243K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,041 | $220K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,004 | $213K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 395 | $201K |
| 80061 | Lipid panel | <1% | 15,311 | $184K |
| 71045 | Radiologic examination, chest; single view | <1% | 10,409 | $183K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 12,497 | $178K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 6,728 | $178K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,828 | $164K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,236 | $161K |
| 76830 | Ultrasound, transvaginal | <1% | 2,151 | $161K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 12,508 | $161K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 12,997 | $159K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 8,960 | $153K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 556 | $152K |
| 76642 | <1% | 1,548 | $144K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 11,139 | $143K |
| 87070 | <1% | 14,950 | $135K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 2,045 | $134K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,082 | $132K |
| 52356 | <1% | 44 | $131K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 6,897 | $124K |
| 76536 | <1% | 1,169 | $121K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 4,373 | $116K |
| 78226 | <1% | 389 | $115K | |
| 84439 | <1% | 15,216 | $113K | |
| 96367 | <1% | 2,754 | $99K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 429 | $97K |
| 87088 | <1% | 17,225 | $96K | |
| 97161 | <1% | 2,256 | $93K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,122 | $93K |
| 70486 | <1% | 718 | $85K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,053 | $84K |
| 76770 | <1% | 697 | $84K | |
| 82607 | <1% | 6,095 | $81K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 81 | $80K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 3,438 | $79K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,001 | $75K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,479 | $75K |
| 72100 | <1% | 2,696 | $74K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 3,135 | $74K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 3,072 | $72K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 798 | $71K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 22,695 | $71K |
| 72110 | <1% | 1,380 | $70K | |
| 87800 | <1% | 2,611 | $69K | |
| 93971 | <1% | 1,057 | $68K | |
| 72050 | <1% | 1,797 | $67K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,956 | $65K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,181 | $63K |
| 74022 | <1% | 2,013 | $62K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,801 | $62K |
| 82746 | <1% | 4,336 | $59K | |
| 74178 | <1% | 217 | $57K | |
| 93017 | <1% | 574 | $57K | |
| 87071 | <1% | 6,241 | $55K | |
| 84466 | <1% | 4,791 | $54K | |
| 73562 | <1% | 3,325 | $54K | |
| V2632 | Posterior chamber intraocular lens | <1% | 766 | $54K |
| J2704 | Injection, propofol, 10 mg | <1% | 11,983 | $54K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 108 | $53K |
| 72072 | <1% | 1,389 | $51K | |
| 84702 | <1% | 7,919 | $50K | |
| 80074 | <1% | 1,259 | $50K | |
| 73030 | <1% | 2,652 | $49K | |
| 73630 | <1% | 2,920 | $49K | |
| 73130 | <1% | 2,641 | $47K | |
| 83880 | <1% | 3,264 | $46K | |
| 87077 | <1% | 9,072 | $45K | |
| 82947 | <1% | 9,371 | $43K | |
| 74018 | <1% | 1,819 | $42K | |
| 92526 | <1% | 461 | $42K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,076 | $42K |
| 82565 | <1% | 3,978 | $42K | |
| 77080 | <1% | 1,092 | $42K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,174 | $41K |
| 73610 | <1% | 2,494 | $40K | |
| 58661 | <1% | 13 | $39K | |
| 87186 | <1% | 6,055 | $39K | |
| 94729 | <1% | 607 | $38K | |
| 94060 | <1% | 1,138 | $38K | |
| 84484 | <1% | 8,678 | $37K | |
| 70491 | <1% | 237 | $37K | |
| 94726 | <1% | 601 | $35K | |
| 83690 | <1% | 16,098 | $35K | |
| 81001 | <1% | 18,916 | $34K | |
| 73502 | <1% | 1,425 | $34K | |
| 82728 | <1% | 2,881 | $34K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,061 | $33K |
| 84112 | <1% | 404 | $32K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 10,010 | $31K |
| 85610 | <1% | 11,513 | $31K | |
| 74019 | <1% | 1,280 | $30K | |
| 73110 | <1% | 1,744 | $29K | |
| 96376 | <1% | 1,992 | $29K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 10,566 | $29K |
| 83540 | <1% | 4,996 | $28K | |
| 76870 | <1% | 338 | $28K | |
| 77065 | Tomosynthesis, mammo | <1% | 941 | $28K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 14,997 | $28K |
| 87522 | Neg quan hep c or qual rna | <1% | 668 | $27K |
| 83013 | <1% | 464 | $27K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,588 | $26K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,998 | $26K |
| 97165 | <1% | 753 | $25K | |
| 87899 | <1% | 2,457 | $25K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 635 | $24K |
| 95819 | <1% | 244 | $24K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 361 | $24K |
| 86256 | <1% | 928 | $24K | |
| 83735 | <1% | 6,506 | $23K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,314 | $23K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 1,554 | $22K |
| 87493 | <1% | 1,003 | $22K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 286 | $22K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 4,878 | $22K |
| 86665 | <1% | 595 | $21K | |
| 97010 | <1% | 5,130 | $21K | |
| 97014 | <1% | 1,501 | $21K | |
| C2617 | Stent, non-coronary, temporary, without delivery system | <1% | 246 | $20K |
| 84403 | <1% | 841 | $20K | |
| 93798 | <1% | 401 | $20K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 176 | $20K |
| 10060 | <1% | 461 | $20K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,149 | $20K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 3,898 | $20K |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 367 | $19K |
| 88304 | <1% | 1,552 | $19K | |
| 85730 | <1% | 6,102 | $19K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 13 | $19K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 187 | $19K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 1,046 | $18K |
| C1776 | Joint device (implantable) | <1% | 14 | $18K |
| 71101 | <1% | 677 | $18K | |
| 93880 | <1% | 183 | $18K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 181 | $17K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,230 | $17K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,268 | $17K |
| 83516 | <1% | 700 | $17K | |
| 88142 | <1% | 1,039 | $17K | |
| 82570 | <1% | 3,787 | $17K | |
| C1769 | Guide wire | <1% | 681 | $17K |
| 12001 | <1% | 535 | $17K | |
| 82043 | <1% | 3,123 | $17K | |
| 81003 | <1% | 10,923 | $16K | |
| 82553 | <1% | 5,136 | $16K | |
| 82784 | <1% | 749 | $16K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,984 | $15K |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,733 | $15K |
| 74183 | <1% | 36 | $15K | |
| 97113 | <1% | 594 | $14K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,728 | $14K |
| 82550 | <1% | 4,423 | $13K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 307 | $13K |
| 73080 | <1% | 913 | $13K | |
| 81025 | <1% | 2,890 | $13K | |
| 87807 | <1% | 3,274 | $13K | |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 887 | $13K |
| 86803 | <1% | 932 | $13K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,993 | $12K |
| 88307 | <1% | 454 | $12K | |
| 73590 | <1% | 837 | $12K | |
| 36591 | <1% | 347 | $12K | |
| 83970 | <1% | 409 | $12K | |
| 86701 | <1% | 1,380 | $12K | |
| 86696 | <1% | 597 | $12K | |
| 85027 | <1% | 2,224 | $12K | |
| 87040 | <1% | 1,761 | $11K | |
| 86376 | <1% | 807 | $11K | |
| 86039 | <1% | 1,076 | $11K | |
| 86850 | <1% | 2,170 | $11K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,538 | $11K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 94 | $11K |
| 87449 | <1% | 1,262 | $11K | |
| 64450 | <1% | 43 | $10K | |
| 73090 | <1% | 837 | $10K | |
| 86677 | <1% | 1,154 | $10K | |
| 83630 | <1% | 773 | $9K | |
| 85379 | <1% | 1,454 | $9K | |
| 86901 | <1% | 2,626 | $9K | |
| 80076 | <1% | 1,033 | $9K | |
| 82274 | <1% | 1,118 | $9K | |
| 86225 | <1% | 829 | $9K | |
| 87045 | <1% | 1,309 | $9K | |
| 82150 | <1% | 1,469 | $9K | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 300 | $9K |
| 86038 | <1% | 868 | $9K | |
| 86664 | <1% | 553 | $9K | |
| 36600 | <1% | 273 | $8K | |
| 82785 | <1% | 519 | $8K | |
| 83001 | <1% | 473 | $8K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,055 | $8K |
| 87046 | <1% | 1,176 | $8K | |
| 73140 | <1% | 531 | $8K | |
| 86663 | <1% | 571 | $8K | |
| 95811 | <1% | 13 | $8K | |
| 84703 | <1% | 1,663 | $8K | |
| 84146 | <1% | 436 | $8K | |
| 86800 | <1% | 500 | $8K | |
| 86618 | <1% | 517 | $7K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 155 | $7K |
| 72158 | <1% | 16 | $7K | |
| 85652 | <1% | 3,162 | $7K | |
| 86695 | <1% | 565 | $7K | |
| 94618 | <1% | 162 | $7K | |
| 91200 | <1% | 111 | $7K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,134 | $7K |
| 81002 | <1% | 2,197 | $7K | |
| 93970 | <1% | 61 | $7K | |
| 86757 | <1% | 223 | $7K | |
| 86780 | <1% | 608 | $7K | |
| 84550 | <1% | 1,635 | $7K | |
| 70470 | <1% | 39 | $6K | |
| 77336 | <1% | 125 | $6K | |
| 83605 | <1% | 1,806 | $6K | |
| 84481 | <1% | 398 | $6K | |
| 83002 | <1% | 338 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 842 | $6K |
| 86431 | <1% | 1,112 | $6K | |
| 84402 | <1% | 264 | $6K | |
| 88342 | <1% | 359 | $6K | |
| 82803 | <1% | 654 | $5K | |
| 86694 | <1% | 376 | $5K | |
| 86060 | <1% | 789 | $5K | |
| 12011 | <1% | 235 | $5K | |
| 83655 | <1% | 379 | $5K | |
| 73718 | <1% | 15 | $5K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 1,018 | $5K |
| 88360 | <1% | 117 | $5K | |
| 83721 | <1% | 578 | $5K | |
| 97802 | <1% | 131 | $5K | |
| 86403 | <1% | 808 | $5K | |
| A4648 | Tissue marker, implantable, any type, each | <1% | 150 | $5K |
| 86705 | <1% | 422 | $5K | |
| 86140 | <1% | 1,034 | $5K | |
| 87328 | <1% | 487 | $5K | |
| 87329 | <1% | 500 | $5K | |
| 80165 | <1% | 409 | $5K | |
| G0424 | Pulmonary rehabilitation, including exercise (includes monitoring), one hour, per session, up to two sessions per day | <1% | 135 | $4K |
| 86707 | <1% | 390 | $4K | |
| 84100 | <1% | 1,171 | $4K | |
| 86003 | <1% | 93 | $4K | |
| 78264 | <1% | 39 | $4K | |
| 70496 | <1% | 39 | $4K | |
| 72082 | <1% | 76 | $4K | |
| 83883 | <1% | 238 | $4K | |
| 74420 | <1% | 66 | $4K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,062 | $4K |
| 29125 | <1% | 129 | $4K | |
| 96523 | <1% | 113 | $3K | |
| 84156 | <1% | 1,181 | $3K | |
| 85007 | <1% | 1,423 | $3K | |
| 87350 | <1% | 305 | $3K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 1,521 | $3K |
| 83615 | <1% | 514 | $3K | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 880 | $3K |
| 83014 | <1% | 435 | $3K | |
| 96417 | <1% | 49 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,004 | $3K |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 696 | $3K |
| 97022 | <1% | 384 | $3K | |
| 88108 | <1% | 176 | $3K | |
| 87902 | <1% | 12 | $3K | |
| 73552 | <1% | 199 | $3K | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 565 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 1,435 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 297 | $3K |
| 90715 | <1% | 366 | $3K | |
| 73523 | <1% | 86 | $3K | |
| 86900 | <1% | 1,367 | $3K | |
| 77417 | <1% | 61 | $3K | |
| 86141 | <1% | 280 | $3K | |
| 83010 | <1% | 195 | $2K | |
| 73060 | <1% | 193 | $2K | |
| 86704 | <1% | 212 | $2K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 271 | $2K |
| 86235 | <1% | 41 | $2K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 383 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,406 | $2K |
| 84460 | <1% | 390 | $2K | |
| 83525 | <1% | 168 | $2K | |
| 74230 | <1% | 70 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 847 | $2K |
| 93922 | <1% | 16 | $2K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 22 | $2K |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 560 | $2K |
| 12002 | <1% | 44 | $2K | |
| 86706 | <1% | 187 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 177 | $2K |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 294 | $2K |
| 78306 | <1% | 27 | $2K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 111 | $2K |
| 82247 | <1% | 299 | $2K | |
| 72040 | <1% | 48 | $2K | |
| 84165 | <1% | 189 | $2K | |
| 84270 | <1% | 85 | $2K | |
| 82977 | <1% | 216 | $2K | |
| 87340 | <1% | 187 | $2K | |
| 82310 | <1% | 132 | $2K | |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | <1% | 103 | $2K |
| 96415 | <1% | 46 | $1K | |
| 76000 | <1% | 81 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 53 | $1K |
| 84436 | <1% | 218 | $1K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 191 | $1K |
| 82248 | <1% | 282 | $1K | |
| 72170 | <1% | 54 | $1K | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 13 | $1K |
| 88300 | <1% | 210 | $1K | |
| 84153 | <1% | 79 | $1K | |
| 82103 | <1% | 90 | $1K | |
| 72220 | <1% | 50 | $1K | |
| 89051 | <1% | 444 | $1K | |
| 85014 | <1% | 910 | $926.84 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 12 | $920.95 |
| C1758 | Catheter, ureteral | <1% | 16 | $904.56 |
| 86592 | <1% | 214 | $873.99 | |
| 87529 | <1% | 27 | $869.43 | |
| 80047 | <1% | 286 | $856.54 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | <1% | 141 | $834.40 |
| 85046 | <1% | 170 | $822.89 | |
| 88302 | <1% | 104 | $776.22 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 46 | $765.61 |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 31 | $764.12 |
| 80320 | <1% | 87 | $761.39 | |
| 84144 | <1% | 39 | $748.87 | |
| J1815 | Injection, insulin, per 5 units | <1% | 565 | $743.85 |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 97 | $710.34 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 1,352 | $703.91 |
| 82077 | <1% | 53 | $673.57 | |
| 87205 | <1% | 212 | $661.32 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 191 | $631.46 |
| 84450 | <1% | 127 | $629.53 | |
| 82525 | <1% | 59 | $625.31 | |
| 97012 | <1% | 78 | $616.91 | |
| 80329 | <1% | 63 | $602.78 | |
| 84479 | <1% | 92 | $592.39 | |
| 97116 | <1% | 134 | $564.73 | |
| 82672 | <1% | 32 | $562.41 | |
| 73560 | <1% | 31 | $533.39 | |
| 0011A | <1% | 36 | $511.18 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 64 | $486.86 |
| 85018 | <1% | 371 | $454.48 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 12 | $441.60 |
| 84480 | <1% | 29 | $427.18 | |
| 80202 | <1% | 29 | $396.07 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 33 | $367.85 |
| 80069 | <1% | 49 | $321.26 | |
| 80143 | <1% | 45 | $309.41 | |
| 84681 | <1% | 14 | $299.01 | |
| 84520 | <1% | 74 | $278.75 | |
| 82009 | <1% | 231 | $276.35 | |
| 80179 | <1% | 45 | $274.46 | |
| 73660 | <1% | 16 | $263.64 | |
| 86200 | <1% | 25 | $262.46 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 812 | $224.87 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 51 | $186.14 |
| 83986 | <1% | 127 | $180.76 | |
| 87102 | <1% | 34 | $166.22 | |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 30 | $154.49 |
| 80178 | <1% | 29 | $150.88 | |
| 84630 | <1% | 26 | $141.78 | |
| 88720 | <1% | 27 | $139.31 | |
| 86709 | <1% | 14 | $125.10 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 13 | $112.09 |
| 82140 | <1% | 13 | $102.92 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 72 | $87.14 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 63 | $86.90 |
| 88311 | <1% | 13 | $81.90 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 272 | $79.58 |
| 82040 | <1% | 12 | $75.60 | |
| 82330 | <1% | 13 | $63.00 | |
| J3070 | Injection, pentazocine, 30 mg | <1% | 231 | $52.31 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | <1% | 17 | $37.19 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 17 | $16.17 |
| A9270 | Non-covered item or service | 0% | 18 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 14 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 119 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 75 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRAY, DAVID (CEO)
| Provider | Location | Paid |
|---|---|---|
| East Sooner Dental Partners PLLC | Midwest City, OK | $1.28M |
| David Christiaan Gray D.M.D.,P.A. | Mcallen, TX | $900K |
| South Side Dental Partners, PLLC | Oklahoma City, OK | $678K |
| Whitewing Dental at LA Feria,pllc | La Feria, TX | $388K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.